Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tinospora sinensis, a member of the Menispermaceae family, is a medicinal plant used extensively in Traditional Chinese, Tibetan, and Ayurvedic medicine. Traditionally known by names such as "Lezhe" in Tibetan, it has been used to treat a wide range of ailments including rheumatic arthralgia, fever, jaundice, diabetes, and various inflammatory conditions. Preclinical research has begun to validate these uses, revealing a multitude of bioactive compounds such as alkaloids (e.g., berberine, palmatine), terpenoids, lignans, and glycosides (e.g., Tinosinenside A). These constituents contribute to its diverse pharmacological activities. The plant's anti-inflammatory and immunomodulatory effects are primarily mediated through the inhibition of pathways like TLR4/NF-κB/NLRP3, which reduces the production of inflammatory cytokines. Other demonstrated mechanisms include α-glucosidase inhibition for diabetes, anticancer effects via ROS-mediated apoptosis and mTOR pathway inhibition in colon cancer cells, and antimalarial activity by targeting parasitic enzymes. Despite its therapeutic potential, its clinical application is not well-established, and it is often confused with or substituted for its close relative, *Tinospora cordifolia*.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tinospora sinensis.